Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an oral antiplatelet agent of the P2Y12 receptor antagonist class. It is a direct-acting, reversible inhibitor of the P2Y12 receptor.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS), including patients who have had a myocardial infarction (MI) with or without ST-segment elevation managed medically or with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for up to 12 months. In some cases, particularly those with a history of MI, treatment may be extended beyond 12 months.
* **Maintenance after MI:** For patients with a history of MI at least one year prior to treatment, ticagrelor 60 mg twice daily may be considered in addition to aspirin to reduce the risk of another thrombotic cardiovascular event.
## Pediatric Dosing
* Dosing in pediatric patients is not established.
## Dose Adjustments
* No dose adjustment is needed for patients with mild to moderate hepatic impairment.
* Use with caution in severe hepatic impairment; safety and efficacy have not been established.
* No dose adjustment is needed based on age, sex, race, or renal impairment.
## Contraindications
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
## Adverse Effects
* **Common:** Dyspnea, bleeding (including fatal and severe bleeding), bruising.
* **Serious:** Hemorrhage, ventricular pauses, bradyarrhythmia.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution.
* **Aspirin:** Generally used concomitantly in ACS; however, doses of aspirin greater than 100 mg may increase bleeding risk.
* **Simvastatin/Atorvastatin:** Ticagrelor can increase the Cmax of simvastatin and atorvastatin. Maximum dose of simvastatin 40 mg daily, and atorvastatin 80 mg daily is recommended.
* **Digoxin:** Ticagrelor can increase digoxin Cmax. Monitor digoxin levels.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Consider monitoring for dyspnea, particularly in patients with pre-existing respiratory conditions.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor and has a faster onset and offset of action compared to clopidogrel.
* Dyspnea is a common side effect and may be transient. If persistent or severe, discontinuation may be considered.
* If possible, discontinue ticagrelor 5 days prior to elective surgery.
* For patients undergoing PCI, continuing ticagrelor beyond 12 months should be based on individual risk assessment for thrombotic events versus bleeding.
* The 60 mg twice daily dose for patients with a history of MI is indicated for long-term use to reduce the risk of thrombotic cardiovascular events.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace current prescribing information. Always consult the most recent product labeling and relevant clinical guidelines before making any treatment decisions.*
